Ethics

J&J marketing triggers $2.2B payout

J&J marketing triggers $2.2B payout

By

The company will shell out $2.2 billion over allegations of marketing misconduct for Risperdal, Invega and Natrecor.

AMA takes on generics and CME

By

The AMA's House of Delegates voted on measures including support for a ban on "pay-for-delay" deals and a recommendation that docs keep the the industry and CME separate.

GSK in biggest-ever $3b marketing fraud settlement

GSK in biggest-ever $3b marketing fraud settlement

By

GlaxoSmithKline will pay $3 billion to settle state and federal charges that it promoted antidepressants Paxil and Wellbutrin for unindicated uses and withheld safety data on diabetes drug Avandia.

GSK values drive flips rep bonus incentives

GSK values drive flips rep bonus incentives

By

The drug industry must move from a mindset that emphasizes compliance with regulations to one steeped in core values of integrity and transparency if it is to regain the public's trust, GSK's Dierdre Connelly said at a conference yesterday.

Email Newsletters